Browse by Audience
MEMBER

Update Your Profile
Special Interest Groups (SIG)
Member Spotlights
IASP Connect
Join Now

RESEARCHER

PAIN
PAIN Reports
Pain Research Forum
Pain Researcher
Events

HEALTH CARE PROVIDER

Online Learning - PERC
Curricula
Graduate Opportunities
Treatment and Education Resources
Events

PATIENT & CAREGIVER

Resources for Living with Pain
Topic Pages
Free Videos
Events

PARTNER

Support IASP
Sponsor an Event
Become a Partner
Make a Donation

I am a
IASP Logo
Home I AM A Search Login

Papers of the Week

Home / Publications / Pain Research Forum / Papers of the Week / Tralokinumab for moderate-to-severe atopic dermatitis patients: first daily practice results.

< BACK TO ARCHIVE


2023 Jan 26


Clin Exp Dermatol


http://www.ncbi.nlm.nih.gov/pubmed/36702810?dopt=Abstract

Tralokinumab for moderate-to-severe atopic dermatitis patients: first daily practice results.

Authors

Tralokinumab for moderate-to-severe atopic dermatitis patients: first daily practice results.
Schlösser AR, Shareef M, Olydam J, Nijsten TEC, Hijnen DJ
Clin Exp Dermatol. 2023 Jan 26.
PMID: 36702810.

Abstract

Evidence on tralokinumab treatment for moderate-to-severe atopic dermatitis (AD) in daily practice is limited.
Read This Paper